START Doses First Patient in Trial of mRNA-4106, a Pan-Tumor Therapy for Solid Tumors

10-Year Results Confirm Pertuzumab Combo Extends Survival in HER2+ Breast Cancer

EpCAM-Targeting ADC CX-2051 Shows Promising Efficacy in Advanced Colorectal Cancer

Leucid Bio Doses First Patient in Trial of LEU011, a CAR-T Therapy for Solid Tumors

POTOMAC Trial: Durvalumab Plus BCG Boosts Outcomes in Early-Stage Bladder Cancer

Enhertu Plus THP Outperforms Standard Chemotherapy in Early-Stage HER2+ Breast Cancer

Elraglusib Shows Survival Benefit in First-Line Metastatic Pancreatic Cancer Trial

Zongertinib Demonstrates 71% Response Rate in HER2-Mutant Lung Cancer Treatment

Bria-IMT’s Early Promise: Biomarkers Signal Path to Personalized Therapy in Breast Cancer

First-Ever KRAS G12D Inhibitor Zoldonrasib Shows 61% Response Rate in Lung Cancer

Bayer Launches First-in-Human Trial of Targeted Alpha Therapy for Advanced Liver Cancer

Gut Bacteria as Co-Therapy: MB097’s Role in Overcoming Resistance in Melanoma

Pembrolizumab Improves Event-Free Survival in Resectable Head and Neck Cancer

New Hope for SPG47: BlackfinBio’s BFB-101 Gene Therapy Advances with FDA Approval

Sasanlimab Plus BCG Shows Significant Survival Benefit for NMI Bladder Cancer

Nimbus Launches First Human Trial of Promising WRN Inhibitor for MSI-H Cancers

Enhertu Redefines First-Line Treatment for HER2+ Metastatic Breast Cancer

Ivonescimab Shows Significant Improvement in First-Line Treatment of NSCLC

First Patient Dosed in Phase 2 Trial of MB-105, CD5 CAR-T Therapy for T-Cell Lymphoma

Trodelvy and Keytruda Combination Marks Breakthrough in mTN-Breast Cancer

SkinJect Patch Shows Early Success in Phase 2 Study for Basal Cell Carcinoma

Durvalumab Shows Significant Survival Benefit in Gastric and GEJ Cancer Treatment

Odronextamab Gains FDA Review for Hard-to-Treat R/R Follicular Lymphoma

Patient Enrollment Completed in VAPOR 2 Trial for Vanquish Prostate Cancer Therapy

Nivolumab Plus Chemotherapy Demonstrates Survival Benefit in Resectable NSCLC

DNA-Based Immunotherapy IMNN-001 Promises to Improve Survival in Ovarian Cancer

Palbociclib Combination Yields PFS Improvement in HR+, HER2+ Breast Cancer

Olaparib Shows Long-term Survival Benefits in BRCA+ and HER2- Breast Cancer

Ribociclib Shows Promising Long-Term Benefits in Early Breast Cancer Treatment

Imlunestrant Shows Promising Results Alone and with Verzenio in ER+, HER2- Breast Cancer